ASP4132 是一种具有口服活性,有效的AMPK激活剂,EC50为 18 nM。ASP4132 具有抗癌活性,可在乳腺癌异种移植小鼠模型中促使肿瘤消退。
生物活性 | ASP4132 is an orally active, potentAMPKactivator with anEC50of 18 nM. ASP4132 has anti-cancer activity and makes tumor regression in breastcancerxenograft mouse models[1]. |
IC50& Target[1] | |
体外研究 (In Vitro) | ASP4132 shows comparable cell growth inhibitory (IC50=0.014 μM) activity against MDA-MB-453 breast cancer cell[1]. ASP4132 shows relatively weak antiproliferative activity against SK-BR-3 (IC50>3 μM)[1].
|
体内研究 (In Vivo) | ASP4132 (0.5-8 mg/kg; PO; once daily; for 21 days) causes the tumor growth inhibition and regression[1]. ASP4132 (1 mg/kg; IV or PO) has a T1/2of 3.6 hours, a CLtotof 19 mL/minokg, and a Vssof 4.6 L/kg for rats for IV[1]. ASP4132 is stable in human liver microsomes (HLM CLint, vitro=61 mL/minokg)[1].
Animal Model: | Five-week-old male nude mice with MDA-MB-453[1] | Dosage: | 0.5, 1, 2, 4, 8 mg/kg | Administration: | PO; once daily; for 21 days | Result: | The tumor growth inhibition (TGI) rate was 29% at 1 mg/kg, and the tumor regression rate was 26%, 87% and 96% at 2, 4 and 8 mg/kg, respectively. |
Animal Model: | Male SD rats[1] | Dosage: | 1 mg/kg (Pharmacokinetic Analysis) | Administration: | IV or PO | Result: | Had a T1/2of 3.6 hours, a CLtotof 19 mL/minokg, and a Vssof 4.6 L/kg for rats for IV. Had a Cmaxof 72 ng/mL and an AUC24hof 705 ng·h/mL for PO. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 250 mg/mL(266.79 mM;Need ultrasonic) 配制储备液 1 mM | 1.0672 mL | 5.3358 mL | 10.6717 mL | 5 mM | 0.2134 mL | 1.0672 mL | 2.1343 mL | 10 mM | 0.1067 mL | 0.5336 mL | 1.0672 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 6.25 mg/mL (6.67 mM); Clear solution
此方案可获得 ≥ 6.25 mg/mL (6.67 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 6.25 mg/mL (6.67 mM); Clear solution
此方案可获得 ≥ 6.25 mg/mL (6.67 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 6.25 mg/mL (6.67 mM); Clear solution
此方案可获得 ≥ 6.25 mg/mL (6.67 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|